temozolomide has been researched along with Ovarian Neoplasms in 12 studies
Ovarian Neoplasms: Tumors or cancer of the OVARY. These neoplasms can be benign or malignant. They are classified according to the tissue of origin, such as the surface EPITHELIUM, the stromal endocrine cells, and the totipotent GERM CELLS.
| Excerpt | Relevance | Reference |
|---|---|---|
| " In this report, we present the case of a 3-year-old girl with glioblastoma who continues to experience an exceptional and durable response (>2 years) to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib." | 7.96 | Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. ( Britt, N; Chudnovsky, Y; Duncan, D; Edgerly, C; Elvin, J; Erlich, RL; Gay, L; Gorelyshev, S; Hemmerich, A; Huang, RSP; Konovalov, A; Kram, DE; McCorkle, J; Miller, V; Ramkissoon, SH; Rankin, A; Ross, JS; Savateev, A; Severson, E; Trunin, Y; Valiakhmetova, A, 2020) |
| " In this report, we present the case of a 3-year-old girl with glioblastoma who continues to experience an exceptional and durable response (>2 years) to the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib." | 3.96 | Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response. ( Britt, N; Chudnovsky, Y; Duncan, D; Edgerly, C; Elvin, J; Erlich, RL; Gay, L; Gorelyshev, S; Hemmerich, A; Huang, RSP; Konovalov, A; Kram, DE; McCorkle, J; Miller, V; Ramkissoon, SH; Rankin, A; Ross, JS; Savateev, A; Severson, E; Trunin, Y; Valiakhmetova, A, 2020) |
| " This paper discusses the early clinical work published showing their use in combination with temozolomide in malignant melanoma, and in familial (BRCA-related) cancers." | 3.74 | PARP inhibitors and cancer therapy - early results and potential applications. ( Jones, C; Plummer, ER, 2008) |
| " The biological effects of two novel PARP inhibitors, NU1025 (8-hydroxy-2-methylquinazolin-4-[3H]one, Ki = 48 nM) and NU1085 [2-(4-hydroxyphenyl)benzamidazole-4-carboxamide, Ki = 6 nM], in combination with temozolomide (TM) or topotecan (TP) have been studied in 12 human tumor cell lines (lung, colon, ovary, and breast cancer)." | 3.70 | Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines. ( Calvert, AH; Curtin, NJ; Delaney, CA; Durkacz, BW; Hostomsky, Z; Kyle, S; Newell, DR; Wang, LZ; White, AW, 2000) |
| "Temozolomide was administered orally at an initial dose of 150 mg/m(2) daily for 5 days, every 4 weeks." | 2.71 | A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer. ( Argenta, PA; Blair Harkness, C; Boente, MP; Carson, LF; Downs, LS; Judson, PL, 2004) |
| "To improve the treatment of women with ovarian cancer, we are investigating the modulation of a prominent DNA-damaging agent, temozolomide, by manipulating the DNA base excision repair (BER) pathway via BER inhibitor, methoxyamine, and overexpression of N-methylpurine DNA glycosylase (MPG)." | 1.34 | Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide. ( Fishel, ML; He, Y; Kelley, MR; Smith, ML, 2007) |
| "Temozolomide is an alkylating agent that mediates its cytotoxic effects via O(6)-methylguanine (O(6)-meG) adducts in DNA." | 1.32 | Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase. ( Barvaux, VA; Gillum, AM; Lorigan, P; Margison, GP; McElhinney, RS; McMurry, TB; Ranson, M, 2004) |
| " To that end, a novel method, based on physiologically based hybrid pharmacokinetic models, is presented to predict human tumor drug concentrations." | 1.32 | Pharmacokinetic model-predicted anticancer drug concentrations in human tumors. ( Bookman, MA; Gallo, JM; Guo, P; Li, S; Ma, J; Orlansky, A; Pulfer, S; Vicini, P; Zhou, F, 2004) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 8 (66.67) | 29.6817 |
| 2010's | 1 (8.33) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yu, ZC | 1 |
| Li, T | 1 |
| Tully, E | 1 |
| Huang, P | 1 |
| Chen, CN | 1 |
| Oberdoerffer, P | 1 |
| Gaillard, S | 1 |
| Shih, IM | 1 |
| Wang, TL | 1 |
| Valiakhmetova, A | 1 |
| Gorelyshev, S | 1 |
| Konovalov, A | 1 |
| Trunin, Y | 1 |
| Savateev, A | 1 |
| Kram, DE | 1 |
| Severson, E | 1 |
| Hemmerich, A | 1 |
| Edgerly, C | 1 |
| Duncan, D | 1 |
| Britt, N | 1 |
| Huang, RSP | 1 |
| Elvin, J | 1 |
| Miller, V | 1 |
| Ross, JS | 1 |
| Gay, L | 1 |
| McCorkle, J | 1 |
| Rankin, A | 1 |
| Erlich, RL | 1 |
| Chudnovsky, Y | 1 |
| Ramkissoon, SH | 1 |
| Grimm, C | 1 |
| Fischer, A | 1 |
| Farrelly, AM | 1 |
| Kalachand, R | 1 |
| Castiglione, R | 1 |
| Wasserburger, E | 1 |
| Hussong, M | 1 |
| Schultheis, AM | 1 |
| Altmüller, J | 1 |
| Thiele, H | 1 |
| Reinhardt, HC | 1 |
| Hauschulz, K | 1 |
| Hennessy, BT | 1 |
| Herwig, R | 1 |
| Lienhard, M | 1 |
| Buettner, R | 1 |
| Schweiger, MR | 1 |
| Jones, C | 1 |
| Plummer, ER | 1 |
| Judson, PL | 1 |
| Blair Harkness, C | 1 |
| Boente, MP | 1 |
| Downs, LS | 1 |
| Argenta, PA | 1 |
| Carson, LF | 1 |
| Barvaux, VA | 1 |
| Lorigan, P | 1 |
| Ranson, M | 1 |
| Gillum, AM | 1 |
| McElhinney, RS | 1 |
| McMurry, TB | 1 |
| Margison, GP | 1 |
| Gallo, JM | 1 |
| Vicini, P | 1 |
| Orlansky, A | 1 |
| Li, S | 1 |
| Zhou, F | 1 |
| Ma, J | 1 |
| Pulfer, S | 1 |
| Bookman, MA | 1 |
| Guo, P | 1 |
| Paik, J | 1 |
| Duncan, T | 1 |
| Lindahl, T | 1 |
| Sedgwick, B | 1 |
| Fishel, ML | 1 |
| He, Y | 1 |
| Smith, ML | 1 |
| Kelley, MR | 1 |
| Jean-Claude, BJ | 1 |
| Mustafa, A | 1 |
| Damian, Z | 1 |
| De Marte, J | 1 |
| Vasilescu, DE | 1 |
| Yen, R | 1 |
| Chan, TH | 1 |
| Leyland-Jones, B | 1 |
| Delaney, CA | 1 |
| Wang, LZ | 1 |
| Kyle, S | 1 |
| White, AW | 1 |
| Calvert, AH | 1 |
| Curtin, NJ | 1 |
| Durkacz, BW | 1 |
| Hostomsky, Z | 1 |
| Newell, DR | 1 |
| Plumb, JA | 1 |
| Strathdee, G | 1 |
| Sludden, J | 1 |
| Kaye, SB | 1 |
| Brown, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Randomized Phase II Study on Decitabine Plus Carboplatin Versus Physician's Choice Chemotherapy in Recurrent, Platinum-resistant Ovarian Cancer.[NCT03467178] | Phase 2 | 119 participants (Anticipated) | Interventional | 2018-07-30 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for temozolomide and Ovarian Neoplasms
| Article | Year |
|---|---|
A phase II evaluation of Temozolomide in patients with recurrent epithelial ovarian cancer.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Alkylating; Dacarbazine | 2004 |
11 other studies available for temozolomide and Ovarian Neoplasms
| Article | Year |
|---|---|
Temozolomide Sensitizes ARID1A-Mutated Cancers to PARP Inhibitors.
Topics: Animals; Antineoplastic Agents; DNA-Binding Proteins; Epigenesis, Genetic; Female; Humans; Mammals; | 2023 |
Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2-Year Durable Response.
Topics: Antineoplastic Agents; Child; Child, Preschool; Female; Glioblastoma; Humans; Neoplasm Recurrence, L | 2020 |
Combined Targeted Resequencing of Cytosine DNA Methylation and Mutations of DNA Repair Genes with Potential Use for Poly(ADP-Ribose) Polymerase 1 Inhibitor Sensitivity Testing.
Topics: BRCA1 Protein; Cell Line, Tumor; Cell Survival; DNA Methylation; DNA Mutational Analysis; E1A-Associ | 2019 |
PARP inhibitors and cancer therapy - early results and potential applications.
Topics: Animals; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Breast Neoplasms; Dacarbazine; En | 2008 |
Sensitization of a human ovarian cancer cell line to temozolomide by simultaneous attenuation of the Bcl-2 antiapoptotic protein and DNA repair by O6-alkylguanine-DNA alkyltransferase.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Apoptosis; Cell Line, Tumor; Dacarbazine; | 2004 |
Pharmacokinetic model-predicted anticancer drug concentrations in human tumors.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Carboplatin; Computer Simu | 2004 |
Sensitization of human carcinoma cells to alkylating agents by small interfering RNA suppression of 3-alkyladenine-DNA glycosylase.
Topics: Antineoplastic Agents, Alkylating; Carmustine; Cell Cycle; Dacarbazine; DNA Glycosylases; Female; Ge | 2005 |
Manipulation of base excision repair to sensitize ovarian cancer cells to alkylating agent temozolomide.
Topics: Antineoplastic Agents, Alkylating; Apoptosis; Base Sequence; Cell Line, Tumor; Dacarbazine; DNA Dama | 2007 |
Cytokinetics of a novel 1,2,3-triazene-containing heterocycle, 8-nitro-3-methyl-benzo-1,2,3,5-tetrazepin-4(3H)-one (NIME), in the human epithelial ovarian cancer cell line OVCAR-3.
Topics: Alkylation; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Azepines; Base Sequence; Bindi | 1999 |
Potentiation of temozolomide and topotecan growth inhibition and cytotoxicity by novel poly(adenosine diphosphoribose) polymerase inhibitors in a panel of human tumor cell lines.
Topics: Antineoplastic Agents; Breast Neoplasms; Cell Division; Cell Survival; Colonic Neoplasms; Dacarbazin | 2000 |
Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter.
Topics: Adaptor Proteins, Signal Transducing; Animals; Antimetabolites, Antineoplastic; Antineoplastic Agent | 2000 |